Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311332210> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W4311332210 endingPage "107815522211455" @default.
- W4311332210 startingPage "107815522211455" @default.
- W4311332210 abstract "Introduction “Secondary exposure to anticancer drugs” refers to exposure to anticancer drugs after chemotherapy via the patient's urine and other excretions. The necessity of countermeasures against secondary exposure to anticancer drugs has been recently highlighted. Although anticancer drugs are also excreted through sweat, few studies have reported exposure to drug residues via this route. We investigated the amount of cyclophosphamide (CPA) excreted in the sweat of patients receiving CHOP therapy (cyclophosphamide, doxorubicin, vincristine, and prednisone). Methods The study population included eight patients with malignant lymphoma who received CHOP therapy between May and December 2021. The amount of CPA in their underwear (namely, cotton short-sleeved shirts) worn from the start of the CHOP therapy until 24 h after the end of CPA administration was measured, using liquid chromatography-mass spectrometry (LC-MS/MS). Results CPA was detected in the underwear of all the patients, with levels ranging between 7.38 and 160.77 ng/cm 2 . No subjective changes were observed in the sweating status of any patients during the study period. Conclusions These results suggested that patients’ sweat, as well as urine, is a potential route for exposure to anticancer drugs. Whether visibly contaminated or not, the clothing and linen worn directly by patients should be handled as a source of sweat-mediated exposure to anticancer drugs both in medical facilities and at home." @default.
- W4311332210 created "2022-12-25" @default.
- W4311332210 creator A5052274966 @default.
- W4311332210 creator A5052778987 @default.
- W4311332210 creator A5064911267 @default.
- W4311332210 creator A5084350427 @default.
- W4311332210 creator A5084933031 @default.
- W4311332210 date "2022-12-13" @default.
- W4311332210 modified "2023-10-16" @default.
- W4311332210 title "Cyclophosphamide exposure via sweat of patients receiving CHOP therapy" @default.
- W4311332210 cites W1500590267 @default.
- W4311332210 cites W1986671465 @default.
- W4311332210 cites W1996690433 @default.
- W4311332210 cites W2021080593 @default.
- W4311332210 cites W2105328493 @default.
- W4311332210 cites W2113275753 @default.
- W4311332210 cites W2952611328 @default.
- W4311332210 cites W4210323032 @default.
- W4311332210 cites W4220717437 @default.
- W4311332210 doi "https://doi.org/10.1177/10781552221145507" @default.
- W4311332210 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36514300" @default.
- W4311332210 hasPublicationYear "2022" @default.
- W4311332210 type Work @default.
- W4311332210 citedByCount "1" @default.
- W4311332210 crossrefType "journal-article" @default.
- W4311332210 hasAuthorship W4311332210A5052274966 @default.
- W4311332210 hasAuthorship W4311332210A5052778987 @default.
- W4311332210 hasAuthorship W4311332210A5064911267 @default.
- W4311332210 hasAuthorship W4311332210A5084350427 @default.
- W4311332210 hasAuthorship W4311332210A5084933031 @default.
- W4311332210 hasConcept C126322002 @default.
- W4311332210 hasConcept C16005928 @default.
- W4311332210 hasConcept C2776694085 @default.
- W4311332210 hasConcept C2776755627 @default.
- W4311332210 hasConcept C2778720950 @default.
- W4311332210 hasConcept C2779429289 @default.
- W4311332210 hasConcept C2779725641 @default.
- W4311332210 hasConcept C2780026642 @default.
- W4311332210 hasConcept C2781303535 @default.
- W4311332210 hasConcept C2908647359 @default.
- W4311332210 hasConcept C63398376 @default.
- W4311332210 hasConcept C71924100 @default.
- W4311332210 hasConcept C98274493 @default.
- W4311332210 hasConcept C99454951 @default.
- W4311332210 hasConceptScore W4311332210C126322002 @default.
- W4311332210 hasConceptScore W4311332210C16005928 @default.
- W4311332210 hasConceptScore W4311332210C2776694085 @default.
- W4311332210 hasConceptScore W4311332210C2776755627 @default.
- W4311332210 hasConceptScore W4311332210C2778720950 @default.
- W4311332210 hasConceptScore W4311332210C2779429289 @default.
- W4311332210 hasConceptScore W4311332210C2779725641 @default.
- W4311332210 hasConceptScore W4311332210C2780026642 @default.
- W4311332210 hasConceptScore W4311332210C2781303535 @default.
- W4311332210 hasConceptScore W4311332210C2908647359 @default.
- W4311332210 hasConceptScore W4311332210C63398376 @default.
- W4311332210 hasConceptScore W4311332210C71924100 @default.
- W4311332210 hasConceptScore W4311332210C98274493 @default.
- W4311332210 hasConceptScore W4311332210C99454951 @default.
- W4311332210 hasLocation W43113322101 @default.
- W4311332210 hasLocation W43113322102 @default.
- W4311332210 hasOpenAccess W4311332210 @default.
- W4311332210 hasPrimaryLocation W43113322101 @default.
- W4311332210 hasRelatedWork W128048152 @default.
- W4311332210 hasRelatedWork W160156331 @default.
- W4311332210 hasRelatedWork W1978407841 @default.
- W4311332210 hasRelatedWork W2044931406 @default.
- W4311332210 hasRelatedWork W2178567417 @default.
- W4311332210 hasRelatedWork W2318073446 @default.
- W4311332210 hasRelatedWork W4236815493 @default.
- W4311332210 hasRelatedWork W4244051174 @default.
- W4311332210 hasRelatedWork W4296529454 @default.
- W4311332210 hasRelatedWork W2183308400 @default.
- W4311332210 isParatext "false" @default.
- W4311332210 isRetracted "false" @default.
- W4311332210 workType "article" @default.